• 1
    Jemal A, Tiwari RC, Murray T et al. Cancer statistics 2004. CA Cancer J Clin 2004; 54: 829
  • 2
    Saad F, Schulman CC. Role of bisphosphonates in prostate cancer. Eur Urol 2004; 45: 2634
  • 3
    Fidler IJ, Yano S, Zhang RD, Fujimaki T, Bucana CD. The seed and soil hypothesis: vascularisation and brain metastases. Lancet Oncol 2002; 3: 537
  • 4
    Garnero P, Buchs N, Zekri J, Rizzoli R, Coleman RE, Delmas PD. Markers of bone turnover for the management of patients with bone metastases from prostate cancer. Br J Cancer 2000; 82: 85864
  • 5
    Saad F, Gleason DM, Murray R et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004; 96: 87982
  • 6
    Weinfurt KP, Li Y, Castel LD, Timbie JW, Glendenning A, Schulman KA. The impact of skeletal-related events on health-related quality of life of patients with metastatic prostate cancer. Ann Oncol 2002; 13 (Suppl. 5): 180, A662P
  • 7
    McKiernan JM, Delea TE, Liss M et al. Impact of skeletal complications on total medical care costs in prostate cancer patients with bone metastases. Proc Am Soc Clin Oncol 2004; 23: 531, A6057
  • 8
    Martel CL, Lara PN. Renal cell carcinoma: current status and future directions. Crit Rev Oncol Hematol 2003; 45: 17790
  • 9
    Flanigan RC, Campbell SC, Clark JI, Picken MM. Metastatic renal cell carcinoma. Curr Treat Options Oncol 2003; 4: 38590
  • 10
    Zekri J, Ahmed N, Coleman RE, Hancock BW. The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 2001; 19: 37982
  • 11
    Lipton A, Zheng M, Seaman J. Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 2003; 98: 9629
  • 12
    Rosen LS, Gordon D, Tchekmedyian NS et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial. Cancer 2004; 100: 261321
  • 13
    Berenson JR, Lichtenstein A, Porter L et al. Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. J Clin Oncol 1998; 16: 593602
  • 14
    Saad F, Gleason DM, Murray R et al. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. J Natl Cancer Inst 2002; 94: 145868
  • 15
    Major PP, Cook RJ, Chen BL, Zheng M. Survival-adjusted multiple event analysis of skeletal complications from bone metastases: a comprehensive analysis of treatment benefit. Presented at the Fourth International Conference on Cancer-Induced Bone Diseases; December 7–9, 2003. San Antonio, Tex: Poster 84
  • 16
    Lipton A, Seaman J, Zheng M. Efficacy and safety of zoledronic acid in patients with bone metastases from renal cell carcinoma. Presented at: What Is New in Bisphosphonates? Seventh Workshop on Bisphosphonates - From the Laboratory to the Patient. Davos, Switzerland. Poster 28, March 2426, 2004
  • 17
    Saad F, Gleason D, Murray R et al. Long-term efficacy and safety of zoledronic acid in men with advanced prostate cancer and bone metastases. Poster presented at the XIXth Congress of the European Association of Urology, Vienna, Austria. March 2427, 2004: 615
  • 18
    Clezardin P. The antitumor potential of bisphosphonates. Semin Oncol 2002; 29 (Suppl. 21): 3342
  • 19
    Santini D, Vincenzi B, Dicuonzo G et al. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients. Clin Cancer Res 2003; 9: 28937
  • 20
    Wood J, Bonjean K, Ruetz S et al. Novel antiangiogenic effects of the bisphosphonate compound zoledronic acid. J Pharmacol Exp Ther 2002; 302: 105561
  • 21
    Dekel Y, Koren R, Kugel V, Livne PM, Gal R. Significance of angiogenesis and microvascular invasion in renal cell carcinoma. Pathol Oncol Res 2002; 8: 12932
  • 22
    Corey E, Brown LG, Quinn JE et al. Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res 2003; 9: 295306